BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35848137)

  • 1. Molecular and expressional characterization of tumor heterogeneity in pulmonary carcinosarcoma.
    Ohtaki Y; Kawabata-Iwakawa R; Nobusawa S; Goto Y; Shimizu K; Yajima T; Nakazawa S; Kawatani N; Yoshida Y; Sano T; Shirabe K
    Mol Carcinog; 2022 Oct; 61(10):924-932. PubMed ID: 35848137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma.
    Zhao J; Xiang C; Zhao R; Guo P; Zheng J; Han-Zhang H; Yu K; Zhang J; Han Y
    BMC Cancer; 2020 Mar; 20(1):248. PubMed ID: 32209061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal carcinosarcoma with basaloid squamous carcinoma and rhabdomyosarcoma components with TP53 mutation.
    Amatya VJ; Takeshima Y; Kaneko M; Inai K
    Pathol Int; 2004 Oct; 54(10):803-9. PubMed ID: 15482572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-Generation Sequencing Analysis Identified Genomic Alterations in Pathological Morphologies of 3 Cases of Pulmonary Carcinosarcoma.
    Li F; Hu S; Kong K; Cao P; Han P; Deng Y; Zhao B
    Onco Targets Ther; 2020; 13():7963-7972. PubMed ID: 32848420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
    Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
    Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.
    Fallet V; Saffroy R; Girard N; Mazieres J; Lantuejoul S; Vieira T; Rouquette I; Thivolet-Bejui F; Ung M; Poulot V; Schlick L; Moro-Sibilot D; Antoine M; Cadranel J; Lemoine A; Wislez M
    Ann Oncol; 2015 Aug; 26(8):1748-53. PubMed ID: 25969368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
    Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
    J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum of
    Basdemirci M; Zamani A; Zamani AG; Findik S; Yildirim MS
    Indian J Cancer; 2022; 59(2):236-243. PubMed ID: 34380837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation sequencing analysis identifies genomic alterations in pathological morphologies: A case of pulmonary carcinosarcoma harboring EGFR mutations.
    Koba H; Kimura H; Nishikawa S; Sone T; Abo M; Hara J; Hosomichi K; Tajima A; Kasahara K
    Lung Cancer; 2018 Aug; 122():146-150. PubMed ID: 30032823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
    Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
    Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
    Vatan O; Bilaloglu R; Tunca B; Cecener G; Gebitekin C; Egeli U; Yakut T; Urer N
    Tumori; 2007; 93(5):473-7. PubMed ID: 18038880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
    Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
    Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Mediastinal Carcinosarcoma With Beta-HCG Production and KRAS Mutation.
    Shaker N; Amadi CC; Welliver M; Otterson GA; Liebner DA; Shilo K
    Int J Surg Pathol; 2023 Dec; 31(8):1598-1604. PubMed ID: 37013353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.